Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Risk assessment in hematologic diseases].

H Linker

    Versicherungsmedizin
    |January 1, 1989
    PubMed
    Summary
    This summary is machine-generated.

    Securing life and work insurance is rare for individuals with hematological diseases due to their typically fatal nature. While some treatments show promise, most conditions remain terminal, with few exceptions like lymphatic leukemia recovery.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Long-term prognosis after kidney transplantation].

    Versicherungsmedizin·1999
    Same author

    [Comprehensive obesity therapy program].

    Versicherungsmedizin·1995
    Same author

    [Thrombopoiesis, thrombocyte count and thrombocyte function before and following cell separation].

    Klinische Wochenschrift·1983
    Same author

    Studies in a case of Bernard-Soulier syndrome.

    Acta haematologica·1983
    Same author

    [Number, function and ultrastructure of peripheral thrombocytes in tropical malaria].

    Die Medizinische Welt·1981
    Same author

    [Ring-shaped inclusions in an uncommon variety of acute myeloid leukemia (author's transl)].

    Blut·1981
    Same journal

    [What do company health insurance plans provide?]

    Versicherungsmedizin·2017
    Same journal

    [Assessment of prescriptive therapies and remedies - Experience and results].

    Versicherungsmedizin·2017
    Same journal

    [The importance of biosimilars medicines for private and statutory health insurance].

    Versicherungsmedizin·2017
    Same journal

    [Can we transfer the mechanisms of the generics market to biosimilars?]

    Versicherungsmedizin·2017
    Same journal

    [Not Available].

    Versicherungsmedizin·2016
    Same journal

    [Not Available].

    Versicherungsmedizin·2016
    See all related articles

    Area of Science:

    • Hematology
    • Oncology
    • Medical Prognosis

    Context:

    • Assessing insurance accessibility for patients with hematological disorders.
    • Understanding the limited insurability due to disease prognosis.
    • Highlighting the challenges in life and work capacity insurance for these patients.

    Purpose:

    • To examine the characteristics, frequency, and prognosis of hematological diseases.
    • To discuss the exceptional cases where insurance is possible.
    • To provide insights into the insurability of patients with blood cancers.

    Summary:

    • Hematological diseases are frequently fatal, making life and work insurance exceptionally difficult.
    • Despite therapeutic advancements, most patients face a predictable, short prognosis.

    Related Experiment Videos

  • Recovery from conditions like lymphatic leukemia represents a rare but significant exception.

    • Impact:

    • Informs the insurance industry about the risks associated with hematological diseases.
    • Provides a realistic outlook for patients and healthcare providers regarding prognosis.
    • Underscores the need for further research into treatments and long-term survival for blood cancer patients.